Elms Steve's Form 4 filing
Adma Biologics, Inc. (ADMA) · filed Mar 15, 2024
- Accession no.
- 0001140361-24-013634
- Filed
- Mar 15, 2024
- Trade date
- Mar 13-15, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $6.34M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Elms SteveCIK 0001250195 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 13, 2024 | Common Stock | SSaleDisposed | −407,000 | $6.21 | −$2,527,470 | 3,208,671 | Indirect | |
| Mar 14, 2024 | Common Stock | SSaleDisposed | −448,276 | $6.05 | −$2,712,069.8 | 2,760,395 | Indirect | |
| Mar 15, 2024 | Common Stock | SSaleDisposed | −183,008 | $6.01 | −$1,099,878.08 | 2,577,387 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.